InsiderDB
Sign inStart free trial

Gilead Sciences (GILD)

Healthcare · Drug Manufacturers - General

20 members of Congress have disclosed 72 trades in Gilead Sciences (GILD) since 2014: 43 buys and 29 sales. The most recent was disclosed on Jul 21, 2026. 1 trade was made by members of a committee that oversees Gilead Sciences's industry.

Trades disclosed
72
Members trading
20
Buys / sells
43 / 29
Reported value
$345K–$1.6M

Keep following the company.

Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.

Follow GILD

What else is happening at GILD

All research →

Company filings and public records connected to this stock, ordered by when they became public or were first observed.

  1. GILDFinancial report·SEC EDGAR

    GILD: 10-Q financial filing

    Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.

    Public: Oct 29, 2026, 8:09 PM EDTEvent / period: Sep 30, 2026Original source ↗
  2. GILDCompany announcement·SEC EDGAR

    GILD: Financial results

    Filed 8-K for an event or period dated 2026-10-29. Financial results.

    Public: Oct 29, 2026, 4:03 PM EDTEvent / period: Oct 29, 2026Original source ↗
  3. GILDLobbying report·Lobbying disclosures

    GILD: third_quarter 2026 lobbying report

    Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Advocate on drug pricing proposals. Proposals to exp

    Public: Oct 21, 2026, 1:36 PM EDTOriginal source ↗
  4. GILDLobbying report·Lobbying disclosures

    GILD: third_quarter 2026 lobbying report

    Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV an

    Public: Oct 20, 2026, 5:56 PM EDTOriginal source ↗
  5. GILDLobbying report·Lobbying disclosures

    GILD: third_quarter 2026 lobbying report

    federal budget issues Lobbying related to pharmaceutical policy Lobbying related to pharmaceutical policy

    Public: Oct 20, 2026, 2:41 PM EDTOriginal source ↗

Committee overlaps

Trades by members of a committee that oversees Gilead Sciences's industry. An overlap is a fact about the trade, not evidence of wrongdoing.

Who traded GILD

All trades

From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.